NeuroproteXeon
Manufacturing · New York, United States · 11-50 Employees
View Company Info for Free
Overview
Headquarters
50 Cobham Dr, Orchard Park, New York, 14...Phone Number
(716) 332-7200Website
www.neuroprotexeon.comRevenue
<$5 MillionIndustry
ZI Rank: 1
Signal Type
Dec
Jan
Feb
Mar
Apr
May
ZI Rank
1
1
1
1
1
1
About NeuroproteXeon
NeuroproteXeon, Inc. is a clinical-stage pharmaceutical/device company developing xenon to improve functional capabilities and survival in patients with Post-Cardiac Arrest Syndrome ("PCAS"). The Company has a license agreement with Mallinckrodt LLC (NYSE:MNK) for the sale and distribution of xenon gas for inhalation in North America, Australia and Japan upon approval of the drug in those markets.Explore more
NeuroproteXeon Org Chart
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is NeuroproteXeon your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
NeuroproteXeon, which may be a good buyer, showed buying intent in Masked Content Topic
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Check if NeuroproteXeon has recently received funding, and reach out quickly before it becomes old news!
Click to see if NeuroproteXeon had a recent Job posting/layoffs
Congratulate Masked Content for being promoted to Masked Content at NeuroproteXeon
Product Launch: Get notified when NeuroproteXeon launches new products
Earning: See what the market has to say on NeuroproteXeon recently announced quarterly report
Funding: Get notified immidiatlly once NeuroproteXeon has new funding data
Check out if NeuroproteXeon is spiking on competitors!
Website visits: Recent activity has been detected on your website
Recommended Actions
Find VP level buyers at NeuroproteXeon
Find 3 more new buyers
Compare Similar Companies to NeuroproteXeon
Compare insights from companies similar to NeuroproteXeon, focusing on performance, financial data, growth rates, and unique benchmarks to identify key industry trends and opportunities.
Revenue
Number of Employees
Type
Funding
Founded In
Company Profile Activity
Activity Insights
NeuroproteXeon is experiencing very low activity levels compared to other companies in the Manufacturing sector.
What does this means?
NeuroproteXeon is drawing exceptional interest within the Manufacturing industry, suggesting notable developments or strong market momentum, learn more about NeuroproteXeon.
NeuroproteXeon Tech Stack
A closer look at the technologies used by NeuroproteXeon
NeuroproteXeon News & Media
Mallinckrodt And NPXe Announce FDA Fast Track Designation For Phase 3 Trial Of Inhaled Xenon Gas Therapy
-- Drug to be studied for improved functional outcomes and survival rates for patients resuscitated after a cardiac arrest -- STAINES-UPON-THAMES, United Kingdom and ABINGDON, United Kingdom and BUFFALO, N.Y., Aug. 23, 2018 /PRNewswire/ -- Mallinckrodt plc (NYSE: MNK), a leading global specialty pharmaceutical company, and NPXe Limited ("NeuroproteXeon" or "NPXe") today announced that the United States Food and Drug Administration (FDA) recently granted Fast Track designation to NPXe's Phase 3 tEuropean Distribution Partnership between NeuroproteXeon and Linde
ABINGDON, England, May 9, 2018 /PRNewswire/ -- NeuroproteXeon announced today that they have completed a distribution agreement with Linde AG (Lin.de) for XENEX™ (xenon by inhalation) for Post Cardiac Arrest Syndrome ("PCAS") for the European Union plus United Kingdom, Switzerland, Norway...
Read more news
Top Manufacturing Companies
Top companies in Australia by revenue
Top companies in New Zealand by revenue
Frequently Asked Questions Regarding NeuroproteXeon
Sign Up For FreeTo access detailed company insights
NeuroproteXeon, Inc. is a clinical-stage pharmaceutical/device company developing xenon to improve functional capabilities and survival in patients with Post-Cardiac Arrest Syndrome ("PCAS"). The Company has a license agreement with Mallinckrodt LLC (NYSE:MNK) for the sale and distribution of xenon gas for inhalation in North America, Australia and... Read More
